We'll be closer to a 26%, 27% growth overall in the year '25, '26. Call transcript, Q4 FY25 · 14 May 2025
Q4 FY25
Q1 FY27:Promise completed and missed in FY26. No new update. Call transcript, Q1 FY27 · 5 Aug 2026
✕Missed
OperationsCore Diagnostics Margin Parity
It will take up to 2 to 3 years to reach the margin Metropolis margin profile. Call transcript, Q3 FY25 · 5 Feb 2025
Q3 FY25
Q1 FY27:Guidance revised again. Target is now 25% margin in 3-4 years from acquisition. This is an improvement from the prior '20%+' target but still below the original 'parity' goal and on an extended timeline. Call transcript, Q1 FY27 · 5 Aug 2026
↑Revised Up
Source: Inve Guidance Tracker for Metropolis Healthcare Limited · to Q1 FY27
A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.
5 of Metropolis Healthcare Limited's 20 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 17 more targets are in the full ledger.
Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
Strengthen presence in North India and drive sustained organic growth.
“the acquisition of DAPIC Dehradun and Scientific Pathology, Agra were completed towards end of the Q1 FY 2027. ... Our recent acquisitions in Agra and Dehradun are also performing very well, with both business tracking ahead of the revenue growth and EBITDA.”
Disclosure indicates an acquisition or investment without specifying full buyout versus minority stake.
Evidence drawer
Evidence type: Transcript excerpt
“the acquisition of DAPIC Dehradun and Scientific Pathology, Agra were completed towards end of the Q1 FY 2027. ... Our recent acquisitions in Agra and Dehradun are also performing very well, with both business tracking ahead of the revenue growth and EBITDA.”
To build a strong genomics platform and strengthen brand in North India. Effective acquisition multiple approximately 10x EBITDA based on FY27 expected generation.
“Core Diagnostics is currently in the final leg of integration. Since it has been a year since the acquisition, it is an appropriate time to reflect on the objectives of the acquisition and the progress we have made against them: ... our effective acquisition multiple would be approximately 10x EBITDA. ... we would like to bring the Core margin to the 25% number. ... at the end of the last quarter, we saw approximately 8% margin for Core. This year, that will obviously move up in this direction but it will take us, like we said, three to four years to get to that number.”
Disclosure indicates an acquisition or investment without specifying full buyout versus minority stake.
Evidence drawer
Evidence type: Transcript excerpt
“Core Diagnostics is currently in the final leg of integration. Since it has been a year since the acquisition, it is an appropriate time to reflect on the objectives of the acquisition and the progress we have made against them: ... our effective acquisition multiple would be approximately 10x EBITDA. ... we would like to bring the Core margin to the 25% number. ... at the end of the last quarter, we saw approximately 8% margin for Core. This year, that will obviously move up in this direction but it will take us, like we said, three to four years to get to that number.”
“Core Diagnostics improved to a high-single-digit margin in quarter 4 '26, while Dehradun, Agra, and Kolhapur acquisitions continue to operate at margins above the company average.”
Disclosure indicates an acquisition or investment without specifying full buyout versus minority stake.
Evidence drawer
Evidence type: Transcript excerpt
“Core Diagnostics improved to a high-single-digit margin in quarter 4 '26, while Dehradun, Agra, and Kolhapur acquisitions continue to operate at margins above the company average.”
Improved profitability and deepened capabilities in genomics.
“For Core Diagnostics, we have committed that within 4 quarters of doing the acquisition, we would move from a negative 2% EBITDA to a high-single-digit EBITDA in Q4. We have completed this mission.”
Disclosure indicates an acquisition or investment without specifying full buyout versus minority stake.
Evidence drawer
Evidence type: Transcript excerpt
“For Core Diagnostics, we have committed that within 4 quarters of doing the acquisition, we would move from a negative 2% EBITDA to a high-single-digit EBITDA in Q4. We have completed this mission.”
Performing as expected, delivering margins better than the group average.
“Our smaller acquisitions, including Dehradun, Agra and Kolhapur continue to perform as expected, delivering margins better than the group average. Overall, by year-end, we expect our acquisition portfolio to demonstrate visible synergy benefits across revenue growth and test mix improvement and channel diversification.”
Disclosure indicates an acquisition or investment without specifying full buyout versus minority stake.
Evidence drawer
Evidence type: Transcript excerpt
“Our smaller acquisitions, including Dehradun, Agra and Kolhapur continue to perform as expected, delivering margins better than the group average. Overall, by year-end, we expect our acquisition portfolio to demonstrate visible synergy benefits across revenue growth and test mix improvement and channel diversification.”
Performing as expected, delivering margins better than the group average.
“Our smaller acquisitions, including Dehradun, Agra and Kolhapur continue to perform as expected, delivering margins better than the group average. Overall, by year-end, we expect our acquisition portfolio to demonstrate visible synergy benefits across revenue growth and test mix improvement and channel diversification.”
Disclosure indicates an acquisition or investment without specifying full buyout versus minority stake.
Evidence drawer
Evidence type: Transcript excerpt
“Our smaller acquisitions, including Dehradun, Agra and Kolhapur continue to perform as expected, delivering margins better than the group average. Overall, by year-end, we expect our acquisition portfolio to demonstrate visible synergy benefits across revenue growth and test mix improvement and channel diversification.”
Performing as expected, delivering margins better than the group average.
“Our smaller acquisitions, including Dehradun, Agra and Kolhapur continue to perform as expected, delivering margins better than the group average. Overall, by year-end, we expect our acquisition portfolio to demonstrate visible synergy benefits across revenue growth and test mix improvement and channel diversification.”
Disclosure indicates an acquisition or investment without specifying full buyout versus minority stake.
Evidence drawer
Evidence type: Transcript excerpt
“Our smaller acquisitions, including Dehradun, Agra and Kolhapur continue to perform as expected, delivering margins better than the group average. Overall, by year-end, we expect our acquisition portfolio to demonstrate visible synergy benefits across revenue growth and test mix improvement and channel diversification.”
Integration progressing well, primary focus on operational alignment, process standardization and cost synergy.
“On the inorganic front, our recent acquisitions are progressing well and are well integrated into the Metropolis system. At Core Diagnostics, the primary focus over the past quarters has been on operational alignment, process standardization and cost synergy. The Q3 margins for Core were expected to be slightly higher than Q2 because the plan was to launch the genomics platform in Q3 '25, which would have meant higher gross margins for these genomics tests. However, due to delay of machine arrival into India, these got launched 3 months later in January '26. And these tests were therefore outsourced at lower gross margins earlier, resulting in a lower EBITDA. However, now these tests have started in-house as of January 26. And in Q4, we expect a meaningful improvement in gross margin, supporting a high single-digit EBITDA margin for Core in Q4 of this year.”
Disclosure indicates an acquisition or investment without specifying full buyout versus minority stake.
Evidence drawer
Evidence type: Transcript excerpt
“On the inorganic front, our recent acquisitions are progressing well and are well integrated into the Metropolis system. At Core Diagnostics, the primary focus over the past quarters has been on operational alignment, process standardization and cost synergy. The Q3 margins for Core were expected to be slightly higher than Q2 because the plan was to launch the genomics platform in Q3 '25, which would have meant higher gross margins for these genomics tests. However, due to delay of machine arrival into India, these got launched 3 months later in January '26. And these tests were therefore outsourced at lower gross margins earlier, resulting in a lower EBITDA. However, now these tests have started in-house as of January 26. And in Q4, we expect a meaningful improvement in gross margin, supporting a high single-digit EBITDA margin for Core in Q4 of this year.”
Similar commentary provides sector context; it does not establish a business relationship with Metropolis Healthcare Limited. Each comparison matches a headwind disclosed by Metropolis Healthcare Limited in the same calendar reporting quarter.
Management states they will pass on inflation to consumers when the market conditions are…
Topic: Raw material costs · Raw material cost · Q1 FY27
Metropolis Healthcare Limited reported: Management states they will pass on inflation to consumers when the market conditions are conducive, implying a managed approach to cost pressures.
Reporting period ended 2026-06-30
22 other companies · Raw material cost
Divi's Laboratories Limited (DIVISLAB) reported (period ended 2026-06-30): Solvent costs remain elevated, and prices can rise suddenly due to geopolitical situations in the Middle East.
Mankind Pharma Limited (MANKIND) reported (period ended 2026-06-30): May see compression in gross margins in the next quarter due to increased commodity prices and dollar strength, though full-year guidance is maintained.
Anthem Biosciences Limited (ANTHEM) reported (period ended 2026-06-30): The Specialty Ingredients business, being more focused on the domestic market, has faced pressure due to raw material turmoil, but decent growth is still expected for the full year.
Acutaas Chemicals Limited (ACUTAAS) reported (period ended 2026-06-30): Geopolitical tensions in the Gulf led to a turbulent start to the financial year, though the team ensured raw material availability and supply continuity.
Evidence drawer
Evidence type: Summary paraphrase
Management states they will pass on inflation to consumers when the market conditions are conducive, implying a managed approach to cost pressures.
Based on the company's own presentations, annual report and earnings calls.
Metropolis Healthcare is a pathology and diagnostics services company that collects patient samples and runs pathology, radiology, wellness and genomics tests through its own labs, earning revenue from both direct-to-patient walk-in/home-collection business (B2C) and contracts with hospitals, doctors, corporates, government health programs and clinical trials (B2B). It operates a network of company-owned, franchised and rural collection centres feeding into a smaller number of central processing laboratories across India, and additionally runs company-managed labs and collection centres in East Africa. The company has expanded its specialty and genomics capabilities through acquisitions such as Core Diagnostics, DAPIC (Dehradun), Scientific Pathology (Agra) and Ambika Pathology (Kolhapur).
Segments
B2C
B2B
Clinical/reference labs
212 labs, including 35 ISO:15189-accredited labs (31 in India, 4 in Kenya) and 2 CAP-accredited labs in India
Sample collection network
5,026 collection centres (own, franchisee and rural)
Geographic reach
Presence across 750+ towns in India, up from 300 towns in FY23
Test menu
4,000+ tests and health profiles offered
Genomics infrastructure
2 CAP-accredited genomics labs, in Mumbai and Gurugram
International footprint
Company-managed labs and collection centres in Kenya, Uganda, Ghana, Zambia and Tanzania; B2B laboratory clients served across 12 other international markets including Abu Dhabi, Bangladesh, Dubai, Maldives, Mauritius, Nepal, Nigeria, Sri Lanka, Uzbekistan, Vietnam and Zimbabwe
Moved an average of ±2.0% across the last 4 priced result releases
Close before → close after
Quarter
Release
Revenue (₹ Cr)
Net profit (₹ Cr)
Rev YoY
Before → After
Reaction
Q1 FY27
5 Aug 26
17
57
−26.1%
₹584.5 → ₹576.75
−1.3%
Q4 FY26
14 May 26
23
51
+475.0%
₹548 → ₹540.7
−1.3%
Q3 FY26
5 Feb 26
26
42
+136.4%
₹1,896 → ₹1,972.5
+4.0%
Q2 FY26
6 Nov 25
23
53
—
₹2,030.8 → ₹2,005.8
−1.2%
The move from the last close before each results date to the first close on or after it — the
market's first read on the quarter alongside what was filed.
Guidance
What management said, and what became of it
4 of 9 judged targets kept · 11 open · verdicts reflect calls analysed to Q1 FY27.
Metropolis Healthcare Limited management guidance track record on Inve: 20 targets tracked across analysed earnings calls (4 achieved, 5 missed, 11 open).
Delivering on Operations (1/2 achieved), while Growth (1 needs watch) is lagging.
Target
Original wording
Said
Latest call
Verdict
OperationsOrganic EBITDA Margin Expansion
Expect the EBITDA to expand by about 1 percentage in this financial year (FY26). Call transcript, Q4 FY25 · 14 May 2025
We'll be closer to a 26%, 27% growth overall in the year '25, '26. Call transcript, Q4 FY25 · 14 May 2025
Q4 FY25
Q1 FY27:Promise completed and missed in FY26. No new update. Call transcript, Q1 FY27 · 5 Aug 2026
✕Missed
OperationsCore Diagnostics Margin Parity
It will take up to 2 to 3 years to reach the margin Metropolis margin profile. Call transcript, Q3 FY25 · 5 Feb 2025
Q3 FY25
Q1 FY27:Guidance revised again. Target is now 25% margin in 3-4 years from acquisition. This is an improvement from the prior '20%+' target but still below the original 'parity' goal and on an extended timeline. Call transcript, Q1 FY27 · 5 Aug 2026
↑Revised Up
Source: Inve Guidance Tracker for Metropolis Healthcare Limited · to Q1 FY27
A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.
No analysed call after Q1 FY27, though results run to Sept 2026.
Call summaries
Q1 FY27 — 5 Aug 2026
Metropolis Healthcare Limited Q1 FY27
Metropolis Healthcare reported a strong Q1 FY27, with revenue growing 17% year-on-year to INR 450 crores, driven by robust volume growth across B2C and B2B segments. Profitability significantly improved, with EBITDA margin expanding 210 basis points to 25.2%. The company reiterated its full-year revenue growth guidance of 14-15% and aims for an EBITDA margin of 27-28% through operational efficiencies and network expansion.
Metropolis Healthcare delivered a strong Q4 and FY26, with MHL Group revenue growing 23.6% to INR 1,646 crores and organic revenue growth of 13.7%, surpassing guidance. The company achieved significant margin expansion, with organic EBITDA margins improving by 140 bps to 25.9% for FY26. Strategic focus on digital engagement, genomics, and operational efficiency, including lab consolidation and network expansion, is driving sustainable growth and profitability.
Metropolis Healthcare delivered a strong Q3 FY26, with robust revenue growth across both group and organic segments, coupled with significant margin expansion for the organic business. The company announced a 3:1 bonus issue and reported progress on acquisitions, despite a one-time impact from Labor Code implementation and a delay in the genomics platform launch for Core Diagnostics.
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Trailing twelve months
17.85% TTM to Sept 2026
Fiscal year
17.81% FY ending Mar 2026
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
36.21%
28.97%
17.44%
15.83%
14.68%
17.81%
How it is calculated. Adjusted EBIT ÷ average capital employed, including minority equity and deposits.
Trailing twelve months
14.07% TTM to Sept 2026
Fiscal year
13.64% FY ending Mar 2026
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
29.78%
25.50%
15.15%
12.09%
11.21%
13.64%
How it is calculated. Adjusted profit attributable to owners ÷ average owners’ equity.
Trailing twelve months
9.91% TTM to Sept 2026
Fiscal year
9.77% FY ending Mar 2026
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
20.91%
16.10%
9.48%
8.35%
8.04%
9.77%
How it is calculated. Total profit excluding exceptional items after tax ÷ average total assets.
Trailing twelve months
25.20% TTM to Sept 2026
Fiscal year
24.67% FY ending Mar 2026
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
29.06%
28.34%
25.52%
23.84%
23.14%
24.67%
How it is calculated. Operating profit ÷ revenue.
Trailing twelve months
13.05% TTM to Sept 2026
Fiscal year
11.85% FY ending Mar 2026
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
18.34%
16.53%
12.46%
10.51%
10.29%
11.85%
How it is calculated. Total profit excluding exceptional items after tax ÷ revenue.
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
22.14%
18.08%
16.90%
16.56%
14.73%
18.23%
How it is calculated. (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
136.07%
117.67%
172.73%
206.25%
180.14%
183.77%
How it is calculated. Operating cash flow ÷ reported total net profit.
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
2.81%
2.52%
4.62%
5.30%
5.18%
3.10%
How it is calculated. Fixed-asset purchases ÷ revenue.
Trailing twelve months
19.89% TTM to Sept 2026
Fiscal year
23.67% FY ending Mar 2026
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
16.59%
23.05%
-6.51%
5.23%
10.18%
23.67%
How it is calculated. Revenue change against the same period one year earlier.
Trailing twelve months
46.10% TTM to Sept 2026
Fiscal year
42.57% FY ending Mar 2026
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
26.21%
10.93%
-30.05%
-11.26%
7.98%
42.57%
How it is calculated. Adjusted profit attributable to owners vs the same period one year earlier.
Trailing twelve months
34.94% TTM to Sept 2026
Fiscal year
31.82% FY ending Mar 2026
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
22.36%
20.00%
-15.80%
-1.71%
6.94%
31.82%
How it is calculated. Operating profit vs the same period one year earlier.
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
0.16×
0.43×
0.27×
0.18×
0.15×
0.15×
How it is calculated. Borrowings ÷ owners’ equity.
Trailing twelve months
12.70× TTM to Sept 2026
Fiscal year
10.12× FY ending Mar 2026
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
21.29×
12.08×
6.87×
7.22×
8.67×
10.12×
How it is calculated. Adjusted EBIT ÷ interest expense.
Trailing twelve months
0.76× TTM to Sept 2026
Fiscal year
0.83× FY ending Mar 2026
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
1.14×
0.97×
0.76×
0.79×
0.78×
0.83×
How it is calculated. Revenue ÷ average total assets.
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
₹-308.00 Cr
₹212.00 Cr
₹173.00 Cr
₹126.00 Cr
₹155.00 Cr
₹170.00 Cr
How it is calculated. Borrowings less cash equivalents.
Trailing twelve months
0.40× TTM to Sept 2026
Fiscal year
0.40× FY ending Mar 2026
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
-1.02×
0.58×
0.56×
0.43×
0.49×
0.40×
How it is calculated. (Borrowings − cash equivalents) ÷ adjusted EBITDA.
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
1.24×
1.42×
1.53×
1.39×
1.28×
1.32×
How it is calculated. Average total assets ÷ closing owners’ equity.
Trailing twelve months
51.34× TTM to Sept 2026
Fiscal year
61.09× FY ending Mar 2026
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
—
—
—
—
—
—
How it is calculated. Current market cap ÷ adjusted profit attributable to owners for the selected income period. Uses current market cap, not the share price at the period end.
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
—
—
—
—
—
—
How it is calculated. Market cap ÷ owners’ equity from the balance sheet selected for the TTM inputs. Uses current market cap, not the share price at the period end.
Trailing twelve months
25.14× TTM to Sept 2026
Fiscal year
28.12× FY ending Mar 2026
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
—
—
—
—
—
—
How it is calculated. (Market cap + borrowings + deposits − cash equivalents) ÷ adjusted EBITDA. Uses current market cap, not the share price at the period end.
Trailing twelve months
2.85% TTM to Sept 2026
Fiscal year
2.44% FY ending Mar 2026
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
—
—
—
—
—
—
How it is calculated. Adjusted EBIT ÷ enterprise value. Uses current market cap, not the share price at the period end.
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
45.00 days
40.00 days
39.00 days
38.00 days
41.00 days
38.00 days
How it is calculated. Reported receivable days from the annual accounts.
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
59.00 days
68.00 days
64.00 days
58.00 days
65.00 days
51.00 days
How it is calculated. Reported inventory days, using material cost / cost of goods sold.
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
160.00 days
136.00 days
136.00 days
150.00 days
171.00 days
146.00 days
How it is calculated. Reported payable days, using material cost / cost of goods sold.
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
-56.00 days
-29.00 days
-33.00 days
-53.00 days
-65.00 days
-57.00 days
How it is calculated. Reported debtor days plus inventory days less payable days.
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
-9.00 days
-26.00 days
-22.00 days
-16.00 days
-18.00 days
-15.00 days
How it is calculated. Reported net working capital days from the annual accounts.
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
22.00%
19.00%
29.00%
16.00%
0.00%
55.00%
How it is calculated. Reported dividend payout as a percentage of annual profit.
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
—
—
—
—
—
—
How it is calculated. Market capitalisation from the current stock record.
A dash means inputs are missing or too old, the ratio does not apply, or the value is outside the supported range. FY uses the reported fiscal period; TTM the latest twelve months; valuations use the current market cap with the chosen earnings period. Screen Indian stocks on these ratios →
Financials
What the filings say
Net profit, year on year: +42% (quarter to sept 2026 against sept 2025).
In ₹ crore. Oldest period first.
Click any row to plot
Line item
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Sept 2026
11
4
23
23
26
23
17
16
251
283
296
321
311
317
339
363
72
62
90
108
95
108
111
134
22.0%
18.0%
23.0%
25.0%
23.0%
25.0%
25.0%
27.0%
3
7
8
1
0
8
5
8
5
5
5
6
6
8
6
7
28
29
31
32
32
39
32
33
42
36
61
71
57
70
78
102
26.0%
19.0%
26.0%
26.0%
26.0%
27.0%
27.0%
26.0%
31
29
45
53
42
51
57
75
1.53
1.41
2.17
2.54
2
2.46
2.73
3.63
Source: Inve data · income statement, quarterly · to Sept 2026
In ₹ crore. Oldest period first.
Click any row to plot
Sales3Y CAGR −56.4%
Operating profit3Y CAGR +11.8%
Net profit3Y CAGR +10.1%
Line item
Mar 2023
Mar 2024
Mar 2025
Mar 2026
1,148
299
41
95
859
925
1,029
1,245
287
283
303
401
15
9
15
17
27
23
20
25
89
94
110
134
188
175
190
259
143
129
145
191
Source: Inve data · income statement, annual · to Mar 2026
In ₹ crore. Oldest period first.
Click any row to plot
Line item
Mar 2023
Mar 2024
Mar 2025
Sept 2025
Mar 2026
Sept 2026
10
10
10
10
41
41
978
1,086
1,321
1,422
1,472
1,600
266
197
204
201
232
268
240
254
324
359
386
431
1,495
1,547
1,859
1,993
2,131
2,341
1,121
1,177
1,447
1,573
1,601
1,637
20
0
0
0
0
0
15
55
71
21
142
271
340
316
341
399
387
433
1,495
1,547
1,859
1,993
2,131
2,341
Source: Inve data · balance sheet · to Sept 2026
In ₹ crore. Oldest period first.
Click any row to plot
Line item
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
249
253
247
264
263
351
63
-736
48
-89
-199
-220
-33
163
-292
-181
-87
-115
279
-321
3
-6
-23
15
221
223
195
200
196
300
Source: Inve data · cash flow · to Mar 2026
In days and %. Oldest period first.
Click any row to plot
Line item
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
45
40
39
38
41
38
59
68
64
58
65
51
160
136
136
150
171
146
-56
-29
-33
-53
-65
-57
-9
-26
-22
-16
-18
-15
36.0%
29.0%
17.0%
16.0%
15.0%
18.0%
22.0%
19.0%
29.0%
16.0%
0.0%
55.0%
Source: Inve data · annual ratios · to Mar 2026
Where revenue comes from
The businesses behind the company’s reported revenue.
Historical breakdown. Showing year ended 31 Mar 2019; this may not reflect the current business mix.
Pathology services contributes 96.6% of reported segment revenue.
Year ended 31 Mar 2019 · Standalone
Pathology services96.6%
₹581.21 crore
Other income3.4%
₹20.52 crore
Reported business segments for year ended 31 Mar 2019
Business segment
Revenue · ₹ crore
Share
Pathology services
581.21
96.6%
Other income
20.52
3.4%
Share = segment revenue ÷ total segment revenue, before intersegment adjustments.
How these numbers add up
Total segment revenue
₹601.73 crore
Intersegment adjustment
Not reported
Net segment revenue
₹601.73 crore
Intersegment transactions are between the company’s own businesses. Net segment revenue can differ from income-statement revenue because reporting definitions differ.
Source: FinEdge · Last checked 19 Sept 2026. Reported segment names are kept as supplied.
Ownership
Who owns it
Promoters hold 47.82% as of Sept 2026; institutions added 1.01 pts since Jun 2026.
Promoters−1.04 pts47.82%
Foreign institutions+0.64 pts11.67%
Domestic institutions+0.37 pts35.49%
Public+0.02 pts5.02%
50,592 shareholders on the register.
Source: Exchange shareholding filings · to Sept 2026 · 8 filings held
Disclosed holders that added to a position or appeared on the register for the first
time, biggest addition first.
Mutual fundnewly disclosed2.81% held
newly disclosed2.51% held
newly disclosed1.09% held
Mutual fund+0.98 pp5.22% held
The same filing shows 3
holders trimming and 2 off the list — both
are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of Metropolis Healthcare Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
Holder
Stake
Change
29.75%
−0.52 pp
10.54%
−0.51 pp
Mutual fund
9.66%
unchanged
7.18%
unchanged
Mutual fund
5.22%
+0.98 pp
Mutual fund
3.79%
unchanged
Mutual fund
2.81%
newly disclosed
2.51%
newly disclosed
Mutual fund
2.26%
−0.58 pp
Mutual fund
2.21%
unchanged
Mutual fund
1.45%
unchanged
1.09%
newly disclosed
A holder disappearing from this list has fallen below the 1% line — it is
not necessarily a sale. Percentages are of total shares, as disclosed in the
company's own filing. Who was buying across the market this quarter.
Mutual funds in METROPOLIS
Filings to Sep 2026
0 new, 0 added, 0 trimmed, 0 sold out
— net +0.00 L shares (+0.0%).
Held by funds
₹1.3k Cr
6 schemes
Biggest holder
HDFC Focused Fund
₹368 Cr · 1.4% of that fund
Scheme
Holding
Last month
Held since
HDFC Focused Fund HDFC Mutual Fund
₹368 Cr
held
Jan '24
HDFC Flexi Cap Fund HDFC Mutual Fund
₹352 Cr
held
Mar '24
Nippon India Small Cap Fund Nippon India Mutual Fund
₹248 Cr
held
Sep '23
HDFC ELSS - Tax Saver Fund HDFC Mutual Fund
₹173 Cr
held
Jan '24
HDFC Aggressive Hybrid Fund HDFC Mutual Fund
₹133 Cr
held
Jan '24
HDFC Pharma and Healthcare Fund HDFC Mutual Fund
₹59 Cr
held
Nov '23
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in
shares, so a price move never looks like buying or selling.
Mutual fundsSep 2026
0 added, 0 trimmed — net 0 shares (+0.0%)
Funds are sitting on
+36%
vs est. average cost
Held by funds
₹1.3k Cr
6 schemes · ≈ 12% of the company
Biggest holder
HDFC Focused Fund
₹368 Cr · 1.4% of that fund
Longest holder
Nippon India Small Cap Fund
3y 1m · since Sep '23
Shares held by these funds+352%
Oct '232.46 cr sharesSep '26
Your own record
Start an Inve Case for Metropolis Healthcare Limited
Free account: one company. Everything above stays public.
Write why you follow Metropolis Healthcare Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Frequently asked questions on Metropolis Healthcare Limited
Compiled directly from METROPOLIS's filed financial statements, earnings call transcripts, and ownership disclosures.
How did Metropolis Healthcare Limited (METROPOLIS) perform in its latest reported quarter (Sept 2026)?
For the quarter ended Sept 2026, Metropolis Healthcare Limited reported revenue of ₹16 Cr, net profit of ₹75 Cr, an operating margin of 27.0%. Diluted earnings per share stood at ₹3.63.
How is Metropolis Healthcare Limited (METROPOLIS) valued today, and what growth does the stock price imply?
Metropolis Healthcare Limited (METROPOLIS) trades at ₹571, with a market capitalization of ₹11.8k Cr.
Who owns Metropolis Healthcare Limited (METROPOLIS) — promoters, FIIs, DIIs, and mutual funds?
As of Sept 2026, Promoters hold 47.8%, FIIs hold 11.7%, DIIs hold 35.5%, Public shareholders hold 5.0%.
Learn to analyse Metropolis Healthcare Limited
Guides on how to read this kind of business and the numbers that matter.
